Insilico Medicine

About the Company

Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

Insilico Medicine Leadership

Alex Zhavoronkov, PhD, Chairman of the Board, Executive Director & CEO
Feng Ren, PhD, Executive Director, Co-CEO, Chief Scientific Officer
Alex Aliper, President
Michelle Chen, Chief Business Officer
Sujata Rao, Chief Medical Officer